BGM Group Ltd.
BGMHealthcare|Drug Manufacturers - Specialty & Generic|CN
$8.25
-0.65 (-7.30%)
Tangible Book / Share
$5.71
Cash / Share
$1.87
Financials
Financial Snapshot
Market Cap
$104.7M
Enterprise Value
$94.3M
Revenue (TTM)
$74.8M
Net Income (TTM)
-$21.7M
Cash & Investments
$11.5M
Net Cash
$10.4M
Free Cash Flow (TTM)
—
Operating CF (TTM)
—
Debt/Equity
0.00
Cash Runway & Burn Rate
Company is cash-flow positive.
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $5.4M | $5.3M | $4.6M | $11.9M | $10.5M | $14.3M | $22.4M | $18.1M | $10.8M | $11.5M | |
| Operating Cash Flow | $2.7M | $4.4M | -$580.2K | $5.1M | $345.0K | $12.7M | $312.2K | $544.2K | -$2.4M | — | |
| Free Cash Flow | $1.2M | $3.3M | -$1.2M | $0.00 | -$3.1M | $9.4M | -$3.4M | -$3.4M | -$4.4M | — | |
| Capital Expenditure | -$1.5M | -$1.1M | -$617.0K | -$458.6K | -$3.5M | -$3.3M | -$3.7M | -$3.9M | -$2.1M | — | |
| Financing Cash Flow | $1.3M | -$3.1M | $507.2K | $2.1M | $24.0M | -$5.9M | -$2.9M | -$491.7K | $2.6M | — |
R&D Spending
R&D (TTM)
$915.3K
R&D Intensity
1.2%
R&D Growth vs Prior
+36.1%
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $22.5M | $50.4M | $46.1M | $50.0M | $57.1M | $64.9M | $46.5M | $25.1M | $37.9M | $74.8M | |
| R&D Expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.2M | $568.5K | $1.4M | $672.7K | $915.3K | |
| R&D % of Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 1.9% | 1.2% | 5.4% | 1.8% | 1.2% | |
| SG&A | $2.3M | $2.2M | $3.5M | $2.7M | $3.3M | $2.9M | $3.8M | $3.3M | $16.8M | $22.8M |
Income Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $22.5M | $50.4M | $46.1M | $50.0M | $57.1M | $64.9M | $46.5M | $25.1M | $37.9M | $74.8M | |
| Cost of Revenue | $19.2M | $42.2M | $36.4M | $42.5M | $51.5M | $58.6M | $44.7M | $21.0M | $33.1M | $65.2M | |
| Gross Profit | $3.4M | $8.1M | $9.7M | $7.5M | $5.6M | $6.2M | $1.8M | $4.1M | $4.8M | $9.6M | |
| R&D | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $1.2M | $568.5K | $1.4M | $672.7K | $915.3K | |
| SG&A | $2.3M | $2.2M | $3.5M | $2.7M | $3.3M | $2.9M | $3.8M | $3.3M | $16.8M | $22.8M | |
| Operating Income | $1.1M | $6.0M | $6.2M | $4.8M | $2.4M | $2.1M | -$2.6M | -$563.8K | -$12.6M | -$14.1M | |
| Interest Expense | $282.8K | $216.2K | $223.7K | $242.9K | $57.7K | $0.00 | $0.00 | $639.5K | $0.00 | $11.3K | |
| Pretax Income | $1.9M | $6.1M | $6.9M | $5.8M | $3.4M | $1.6M | -$7.9M | -$2.1M | -$19.9M | -$21.6M | |
| Net Income | $1.4M | $5.2M | $5.3M | $5.1M | $3.2M | $1.1M | -$7.8M | -$1.4M | -$19.9M | -$21.7M | |
| EPS (Diluted) | 6.00 | 22.20 | 22.80 | 21.60 | 13.50 | 4.50 | -32.40 | -6.00 | -5.40 | -4.29 | |
| EBITDA | $3.4M | $7.6M | $8.4M | $7.2M | $4.2M | $3.7M | -$1.3M | $879.9K | -$11.1M | -$11.7M | |
| Shares Out. (M) | 0.23 | 0.23 | 0.23 | 0.23 | 0.23 | 0.24 | 0.24 | 0.24 | 3.78 | 6.19 |
Balance Sheet
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.4M | $5.3M | $4.6M | $11.9M | $10.5M | $14.3M | $7.5M | $9.8M | $9.8M | $11.5M | |
| Short-Term Investments | $0.00 | $14.6K | $0.00 | $0.00 | $0.00 | $0.00 | $14.9M | $8.3M | $994.9K | $28.4K | |
| Total Current Assets | $22.0M | $22.2M | $25.0M | $37.5M | $40.4M | $30.0M | $34.5M | $29.8M | $51.5M | $45.7M | |
| Total Assets | $33.4M | $33.3M | $35.3M | $48.1M | $75.4M | $64.5M | $51.3M | $53.0M | $433.8M | $436.5M | |
| Total Current Liabilities | $18.0M | $14.3M | $11.7M | $18.4M | $18.2M | $9.2M | $6.7M | $8.8M | $41.6M | $36.6M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $19.7M | $15.6M | $12.6M | $19.3M | $18.7M | $9.6M | $6.9M | $8.9M | $41.7M | $36.6M | |
| Stockholders' Equity | $11.2M | $15.3M | $19.9M | $26.1M | $54.9M | $53.1M | $42.8M | $42.7M | $390.9M | $398.2M | |
| Retained Earnings | $3.1M | $2.9M | $7.6M | $12.2M | $14.7M | $15.5M | $5.9M | $4.3M | -$15.8M | -$17.9M |
Cash Flow Statement
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $2.7M | $4.4M | -$580.2K | $5.1M | $345.0K | $12.7M | $312.2K | $544.2K | -$2.4M | — | |
| Capital Expenditure | -$1.5M | -$1.1M | -$617.0K | -$458.6K | -$3.5M | -$3.3M | -$3.7M | -$3.9M | -$2.1M | — | |
| Free Cash Flow | $1.2M | $3.3M | -$1.2M | $0.00 | -$3.1M | $9.4M | -$3.4M | -$3.4M | -$4.4M | — | |
| Investing Cash Flow | -$1.7M | -$1.4M | -$800.2K | -$375.6K | -$24.2M | -$3.3M | -$4.7M | $983.4K | -$162.9K | — | |
| Financing Cash Flow | $1.3M | -$3.1M | $507.2K | $2.1M | $24.0M | -$5.9M | -$2.9M | -$491.7K | $2.6M | — | |
| Issuance of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $23.9M | $0.00 | $0.00 | $0.00 | $0.00 | — | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | |
| Net Debt Issuance | $1.7M | -$2.6M | $872.5K | $2.1M | $123.7K | -$5.9M | -$1.2M | -$491.7K | $2.6M | — | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $20.0K | $0.00 | $0.00 | $0.00 | — | |
| Net Change in Cash | $2.3M | -$246.1K | -$1.0M | $7.3M | $740.2K | $2.4M | -$7.5M | $2.3M | $3.2K | — |
Dilution Tracker
Shares outstanding grew 1518.0% over 5 years — significant dilution
Shares Outstanding
13M
5-Year Share Growth
+1518.0%
Stock Issuance (TTM)
—
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 0.23 | 0.23 | 0.23 | 0.23 | 0.23 | 0.24 | 0.24 | 0.24 | 3.78 | 6.19 | |
| Change vs Prior % | — | 0.0% | 0.0% | 0.0% | -2.6% | 6.0% | 0.0% | 0.0% | 1467.3% | 63.9% | |
| Stock Issuance | $0.00 | $0.00 | $0.00 | $0.00 | $23.9M | $0.00 | $0.00 | $0.00 | $0.00 | — | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — | |
| Stock Based Comp. | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $20.0K | $0.00 | $0.00 | $0.00 | — |
Margins & Profitability
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 15.0% | 16.1% | 21.0% | 15.1% | 9.9% | 9.6% | 3.8% | 16.4% | 12.8% | 12.9% | |
| Operating Margin % | 5.0% | 11.9% | 13.4% | 9.6% | 4.2% | 3.2% | -5.6% | -2.2% | -33.2% | -18.9% | |
| Net Margin % | 6.3% | 10.3% | 11.6% | 10.1% | 5.5% | 1.7% | -16.7% | -5.7% | -52.6% | -29.0% | |
| EBITDA Margin % | 15.0% | 15.1% | 18.1% | 14.4% | 7.3% | 5.8% | -2.7% | 3.5% | -29.3% | -15.7% | |
| FCF Margin % | 5.1% | 6.6% | -2.6% | 0.0% | -5.5% | 14.5% | -7.3% | -13.5% | -11.7% | — | |
| ROE % | 12.6% | 33.7% | 26.8% | 19.4% | 5.7% | 2.0% | -18.2% | -3.4% | -5.1% | -5.4% | |
| ROA % | 4.2% | 15.5% | 15.1% | 10.5% | 4.2% | 1.7% | -15.2% | -2.7% | -4.6% | -4.9% | |
| ROIC % | 4.2% | 21.7% | 18.4% | 11.0% | 3.4% | 3.2% | -5.8% | -0.9% | -3.2% | -2.8% | |
| R&D / Revenue % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 1.9% | 1.2% | 5.4% | 1.8% | 1.2% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 123.5% | -8.5% | 8.5% | 14.1% | 13.6% | -28.3% | -46.0% | 51.1% | |
| Gross Profit | 0.0% | 140.4% | 19.0% | -22.1% | -25.2% | 10.4% | -71.9% | 134.9% | 17.8% | |
| Operating Income | 0.0% | 428.2% | 3.5% | -22.1% | -50.4% | -12.0% | -224.2% | 78.4% | -2131.7% | |
| Net Income | 0.0% | 265.4% | 3.1% | -5.0% | -37.7% | -65.9% | -822.6% | 81.5% | -1282.1% | |
| EPS (Diluted) | 0.0% | 270.0% | 2.7% | -5.3% | -37.5% | -66.7% | -820.0% | 81.5% | 10.0% | |
| Operating Cash Flow | 0.0% | 65.5% | -113.1% | 974.9% | -93.2% | 3567.5% | -97.5% | 74.3% | -535.9% | |
| Free Cash Flow | 0.0% | 188.2% | -136.1% | 100.0% | 0.0% | 398.4% | -136.2% | 0.4% | -31.0% | |
| R&D Expense | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -53.6% | 139.5% | -50.6% | |
| SG&A Expense | 0.0% | -4.0% | 62.0% | -22.1% | 19.2% | -10.8% | 30.8% | -12.6% | 405.2% | |
| Total Assets | 0.0% | -0.1% | 5.8% | 36.5% | 56.5% | -14.4% | -20.6% | 3.4% | 718.5% | |
| Book Value / Share | 0.0% | 29.8% | 27.7% | 27.4% | 101.7% | -8.5% | -19.3% | -0.6% | -43.3% | |
| Debt | 0.0% | -39.2% | 16.1% | 54.7% | 5.8% | -78.0% | -67.3% | -100.0% | 0.0% | |
| Diluted Shares | 0.0% | 0.0% | 0.0% | 0.0% | -2.6% | 6.0% | 0.0% | 0.0% | 1467.3% |
Valuation
P/E (TTM)At Loss
10Y Low / Med / High7.24 / 12.22 / 36.67
P/S2.19
10Y Low / Med / High0.61 / 0.84 / 30.59
P/B0.13
10Y Low / Med / High0.68 / 1.48 / 3.42
EV/EBITDAAt Loss
10Y Low / Med / High4.65 / 7.27 / 54.46
EV/Revenue1.97
10Y Low / Med / High0.42 / 0.74 / 30.38
P/FCF71.67
10Y Low / Med / High4.23 / 11.59 / 33.41
Intrinsic Value Models (per share)
Tangible Book / Share
$5.71
Net Current Assets / Share
$0.72
Cash / Share
$1.87
| Metric | Trend | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | 27.50 | 7.43 | 7.24 | 7.64 | 12.22 | 36.67 | -5.09 | -39.95 | -56.89 | -1.70 | |
| P/S Ratio | 1.71 | 0.76 | 0.84 | 0.77 | 0.66 | 0.61 | 0.86 | 2.30 | 30.59 | 2.19 | |
| P/B Ratio | 3.42 | 2.51 | 1.94 | 1.48 | 0.68 | 0.75 | 0.93 | 1.35 | 2.97 | 0.13 | |
| EV/EBITDA | 11.84 | 4.92 | 4.65 | 4.74 | 8.44 | 7.27 | -25.77 | 54.46 | -103.60 | -10.20 | |
| EV/Revenue | 1.78 | 0.74 | 0.84 | 0.68 | 0.61 | 0.42 | 0.71 | 1.91 | 30.38 | 1.97 |
Analyst Estimates & Quality
Altman Z-Score
1.83
Grey Zone
Piotroski F-Score
3
Weak
Dividends
Frequency
Special
Recent Payments
| Ex-Date | Pay Date | Amount | Frequency |
|---|---|---|---|
| Feb 27, 2023 | Mar 6, 2023 | $0.25 | Special |